We next investigated the combined prognostic impact of MGMT and TGFB1/2/3 methylations in a young cohort of GBM patients to evaluate whether MGMT and TGFB1/2/3 methylations further prolonged survival times (upper quartile percentile cut-off for high methylation levels and age at diagnosis; the median cut-off for young patients (<60 years) was used for both male and female patients to obtain sufficient sample sizes for statistical comparisons) (Figure 1). Here, MGMT is linked to glioblastoma.